119 related articles for article (PubMed ID: 38442621)
1. Predicting amyloid positivity from FDG-PET images using radiomics: A parsimonious model.
Rasi R; Guvenis A;
Comput Methods Programs Biomed; 2024 Apr; 247():108098. PubMed ID: 38442621
[TBL] [Abstract][Full Text] [Related]
2. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
4. Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease.
Jiang J; Wang M; Alberts I; Sun X; Li T; Rominger A; Zuo C; Han Y; Shi K; Initiative FTADN
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2163-2173. PubMed ID: 35032179
[TBL] [Abstract][Full Text] [Related]
5. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
6. Tracer-specific reference tissues selection improves detection of
Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
[TBL] [Abstract][Full Text] [Related]
7. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
9. Radiomics Analysis of Brain [
Alongi P; Laudicella R; Panasiti F; Stefano A; Comelli A; Giaccone P; Arnone A; Minutoli F; Quartuccio N; Cupidi C; Arnone G; Piccoli T; Grimaldi LME; Baldari S; Russo G
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453981
[TBL] [Abstract][Full Text] [Related]
10. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
[TBL] [Abstract][Full Text] [Related]
12. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
13. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
14. Predicting MCI progression with FDG-PET and cognitive scores: a longitudinal study.
Teng L; Li Y; Zhao Y; Hu T; Zhang Z; Yao Z; Hu B;
BMC Neurol; 2020 Apr; 20(1):148. PubMed ID: 32316912
[TBL] [Abstract][Full Text] [Related]
15. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
16. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
[TBL] [Abstract][Full Text] [Related]
17. Radiomics: a novel feature extraction method for brain neuron degeneration disease using
Li Y; Jiang J; Lu J; Jiang J; Zhang H; Zuo C
Ther Adv Neurol Disord; 2019; 12():1756286419838682. PubMed ID: 30956687
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic value of amyloid PET textural and shape features: comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database.
Ben Bouallègue F; Vauchot F; Mariano-Goulart D; Payoux P
Brain Imaging Behav; 2019 Feb; 13(1):111-125. PubMed ID: 29427064
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
20. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
